Wave Life Sciences Ltd.
Ticker
WVE
ISIN
SG999901471
Price
USD 6.26
Change Today
+0.36 / 6.102 %
Price 1 year ago
4.03 / 55.335 %
Market Capitalization
185,910,704.00
52 Week Low
3.51
52 Week High
6.87
200 Day Moving Average
5.17
50-day Moving Average
5.77
Price evolution
Yearly Returns
Peers
Peers
Company information
Summary
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional proteins, or modulate protein expression. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders. In addition, it focuses on developing GalNAc-conjugated AIMers to treat hepatic indications comprising Alpha-1 antitrypsin deficiency (AATD); and two preclinical programs, such as Usher syndrome type 2A (USH2A) and retinitis pigmentosa due to a P23H mutation in the RHO gene (RhoP23H) for the treatment of retinal diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, University of Oxford, University of Massachusetts, Western Washington University, Grenoble Institute of Neurosciences, IRBM S.p.A, University of Louisville, and University College London. The company was incorporated in 2012 and is based in Singapore.
Sector
Healthcare
Industry
Biotechnology
Country
Singapore
Exchange
NGM
Earnings Per Share
-3.822
P/E Ratio
-
Debt/Equity Ratio
367.434
Beta
-0.414644
Ebitda
-114,374,000.00
Ebitda Margins
-2.68
Enterprise to Ebitda
-0.70
Enterprise Value
80,471,024.00
Target Price
8.57
Estimated Price
-
Book Value
1.70
Expected Growth
-
Balance sheet
Income statement
Sustainability
Correlation
| Company | Name | Correlation |
|---|---|---|
| RIGL | Rigel Pharmaceuticals, Inc. | -0.18 |
| DNA | Ginkgo Bioworks Holdings, Inc. | -0.15 |
| 2370.T | MEDINET CO LTD | -0.12 |
| 9939.HK | KINTOR PHARMA-B | -0.06 |
| IMU.AX | IMUGENE FPO | -0.02 |
| 1177.HK | SINO BIOPHARM | 0.03 |
| NVAX | Novavax, Inc. | 0.04 |
| 2269.HK | WUXI BIO | 0.07 |
| BLUE | bluebird bio, Inc. | 0.21 |
| CLVS | Clovis Oncology, Inc. | 0.60 |
Similar companies
| Ticker | Name | City | Country | Currency | Exchange | Beta | EV/EBITDA | Employees | Site |
|---|---|---|---|---|---|---|---|---|---|
| ALPHA.PA | PHARNEXT | Issy-les-Moulineaux | France | EUR | PAR | 2.86 | -0.65 | 40 | https://www.pharnext.com |
| 1177.HK | SINO BIOPHARM | Wan Chai | Hong Kong | HKD | HKG | 0.48 | 17.58 | 25579 | https://www.sinobiopharm.com |
| 0775.HK | CKLIFE SCIENCES | Tai Po | Hong Kong | HKD | HKG | 0.40 | 32.46 | 1855 | https://www.ck-lifesciences.com |
| DNA | Ginkgo Bioworks Holdings, Inc. | Boston | United States | USD | NYQ | -1.24 | 641 | https://www.ginkgobioworks.com | |
| 002252.SZ | S/H RAAS BLOOD PRO | Shanghai | China | CNY | SHZ | 0.21 | 19.62 | 2966 | https://www.raas-corp.com |
| 002007.SZ | HUALAN BIOLOGICAL | Xinxiang | China | CNY | SHZ | 0.03 | 19.25 | 2927 | https://www.hualanbio.com |
| 600200.SS | JIANGSU WUZHONG PHARMACEUTICAL | Suzhou | China | CNY | SHH | 0.56 | -710.43 | https://www.600200.com | |
| 600866.SS | STAR LAKE BIOSCIENCE CO INC Z | Zhaoqing | China | CNY | SHH | 0.35 | 21.35 | 2608 | https://www.starlake.com.cn |
| TRX.L | TISSUE REGENIX GROUP PLC | Garforth | United Kingdom | GBp | LSE | 1.40 | -10.94 | 79 | https://www.tissueregenix.com |
| 2269.HK | WUXI BIO | Wuxi | China | HKD | HKG | 0.91 | 85.17 | 9864 | https://www.wuxibiologics.com |
| IMU.AX | IMUGENE FPO | Sydney | Australia | AUD | ASX | 2.28 | -30.30 | https://www.imugene.com | |
| 600201.SS | JINYU BIO-TECHNOLOGY CO LTD | Hohhot | China | CNY | SHH | 0.31 | 18.76 | 1580 | https://www.jinyu.com.cn |
| TMBR | Timber Pharmaceuticals, Inc. | Basking Ridge | United States | USD | ASE | 0.19 | 5 | https://www.timberpharma.com | |
| 300181.SZ | ZHEJIANG JOLLY PHA | Huzhou | China | CNY | SHZ | 0.10 | 18.50 | 2132 | https://www.zuoli.com |
| CLVS | Clovis Oncology, Inc. | Boulder | United States | USD | NMS | 0.49 | -3.78 | 413 | https://www.clovisoncology.com |
| ATHX | Athersys, Inc. | Cleveland | United States | USD | NCM | -1.30 | -0.60 | 104 | https://www.athersys.com |
| VTGN | VistaGen Therapeutics, Inc. | South San Francisco | United States | USD | NCM | 1.06 | 0.75 | 36 | https://www.vistagen.com |
| 300009.SZ | ANHUI ANKE BIOTECH | Hefei | China | CNY | SHZ | 0.38 | 19.32 | https://www.ankebio.com | |
| 300122.SZ | CHONGQING ZHIFEI B | Chongqing | China | CNY | SHZ | 0.77 | 11.89 | 4800 | https://www.zhifeishengwu.com |
| 2370.T | MEDINET CO LTD | Tokyo | Japan | JPY | JPX | 1.34 | -2.69 | 92 | https://www.medinet-inc.co.jp |
| 2137.HK | BRII-B | Beijing | China | HKD | HKG | -5.41 | 113 | https://www.briibio.com | |
| 1530.HK | 3SBIO | Shenyang | China | HKD | HKG | 0.84 | 6.75 | 5292 | https://www.3sbio.com |
| 1801.HK | INNOVENT BIO | Suzhou | China | HKD | HKG | -0.31 | -14.04 | 5568 | https://www.innoventbio.com |
| 300497.SZ | JIANGXI FUSHINE PH | Jingdezhen | China | CNY | SHZ | 0.14 | 35.19 | 1849 | https://www.fushine.cn |
| 300147.SZ | XIANGXUE PHARMACEU | Guangzhou | China | CNY | SHZ | 0.59 | 374.63 | 3378 | https://www.xphcn.com |
| BLUE | bluebird bio, Inc. | Cambridge | United States | USD | NMS | 1.38 | -0.35 | 518 | https://www.bluebirdbio.com |
| 300204.SZ | STAIDSON (BEIJING) | Beijing | China | CNY | SHZ | 0.16 | -27.06 | 873 | https://www.staidson.com |
| AKBA | Akebia Therapeutics, Inc. | Cambridge | United States | USD | NGM | 1.47 | -0.16 | 426 | https://www.akebia.com |
| 1873.HK | VIVA BIOTECH | Shanghai | China | HKD | HKG | 0.95 | 15.94 | 2127 | https://www.vivabiotech.com.cn |
| 300363.SZ | PORTON PHARMA SOLU | Chongqing | China | CNY | SHZ | -0.36 | 30.90 | 4158 | https://www.porton.cn |
| VLON | Vallon Pharmaceuticals Inc. | Philadelphia | United States | USD | NCM | -1.15 | -0.24 | 2 | https://www.vallon-pharma.com |
| SRNE | Sorrento Therapeutics, Inc. | San Diego | United States | USD | NCM | 2.17 | -2.59 | 799 | https://www.sorrentotherapeutics.com |
| NVAX | Novavax, Inc. | Gaithersburg | United States | USD | NMS | 1.58 | -2.58 | 1541 | https://www.novavax.com |
| 300759.SZ | PHARMARON BEIJING | Beijing | China | CNY | SHZ | 0.28 | 49.23 | 14923 | https://www.pharmaron.com |
| 300404.SZ | BOJI MEDICAL & TEC | Guangzhou | China | CNY | SHZ | -0.10 | 63.41 | 989 | https://www.bojicro.com |
| RIGL | Rigel Pharmaceuticals, Inc. | South San Francisco | United States | USD | NMS | 1.66 | -2.33 | 165 | https://www.rigel.com |
| 688180.SS | SHANGHAI JUNSHI BIOSCIENCES CO | Shanghai | China | CNY | SHH | 0.24 | -39.92 | 2805 | https://www.junshipharma.com |
| 600161.SS | BEIJING TIANTAN BIOLOGICAL PROD | Beijing | China | CNY | SHH | 0.02 | 23.29 | 3933 | https://www.tiantanbio.com |
| 9939.HK | KINTOR PHARMA-B | Suzhou | China | HKD | HKG | -0.77 | -5.99 | 316 | https://www.kintor.com.cn |
| VERU | Veru Inc. | Miami | United States | USD | NCM | -0.41 | -41.18 | 252 | https://www.verupharma.com |
Funds
Mutual Fund Holders
Social
Dividends
Ratings
News
Earnings
SEC Filings
Options
Indicators
Glossary
- Momentum
- A technical indicator that measures the rate of change in price movements over a specific period. It indicates the strength or weakness of a price trend.
Assessment: A positive momentum value generally indicates a good trend, while a negative value suggests a weak or downward trend.
- Inertia
- In trading, inertia refers to the tendency of prices to continue moving in their current direction. It suggests that an asset's price will likely maintain its current trend.
Assessment: A higher inertia value is generally considered good, as it indicates a strong and sustained price trend.
- Relative Strength Index (RSI)
- A momentum oscillator that measures the speed and change of price movements. It helps identify overbought or oversold conditions in an asset.
Assessment: An RSI value above 70 is typically considered overbought and may suggest a potential reversal or correction. Conversely, an RSI value below 30 is often considered oversold, indicating a possible upward price correction.
- Fibonacci's Weighted Moving Average
- A technical indicator that assigns different weights to recent data points, giving more significance to recent prices. It helps smooth out price fluctuations and identify trend reversals.
Assessment: The interpretation of the Fibonacci's Weighted Moving Average value depends on its comparison to other moving averages or trendlines. A value above 50 may indicate an uptrend, while a value below 50 may suggest a downtrend.
- Williams %R
- A momentum indicator that measures overbought or oversold conditions in an asset. It shows the relationship of the current closing price to the high-low range over a specified period.
Assessment: Williams %R values above -20 are typically considered overbought and may indicate a potential price reversal. Values below -80 are often viewed as oversold, suggesting a potential price bounce.
- Relative Volatility Index (RVI)
- A technical indicator that measures the volatility of a security by comparing the magnitude of recent price movements to the magnitude of average price changes. It helps identify periods of high or low volatility.
Assessment: A higher RVI value suggests higher volatility, which can provide trading opportunities but also carries increased risk.
- Commodity Channel Index (CCI)
- A versatile indicator that measures the current price level relative to an average price level over a given period. It helps identify overbought or oversold conditions and potential trend reversals.
Assessment: CCI values above 100 are often considered overbought, indicating a potential price correction or reversal. Values below -100 are typically viewed as oversold, suggesting a potential price rebound.